Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Engraftment achieved after conditioning without radiation, alkylating agents

Publish date:: March 14, 2019

Key clinical point: An alemtuzumab/fludarabine conditioning regimen, without any radiation or alkylating agents, was effective in patients with dyskeratosis congenita who experienced myeloid failure.

Major finding: In total, 95% of patients with dyskeratosis congenita achieved primary engraftment at a median of 22 days after transplant.

Study details: A prospective, multicenter study including 20 patients with dyskeratosis congenita aged from 30 months to 65 years.

Disclosures: Dr. Agarwal reported having no conflicts of interest.

Citation:

Agarwal S et al. TCT 2019, Abstract LBA2.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Cellular Therapy

CAR T-cell therapy may worsen mental health in some patients,

New Toxicity Subscale Measures QOL in Cancer Patients on Checkpoint Inhibitors,

CAR T cells produce complete responses in T-cell malignancies,

CAR T-cell therapy advances in CLL,

Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients,